The expanded agreement is based on positive initial data using Exai’s platform in the trial, which demonstrated that oncRNAs were a significant predictor of patient outcomes. I-SPY 2 is the largest and longest-running 'platform' trial that provides a regulatory framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer.
Exai Bio is founded on discoveries by Associate Professor Hani Goodarzi, PhD, at UC San Francisco.